



PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 76309

Title: Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03650105

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: India

Manuscript submission date: 2022-03-11

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-16 05:13

Reviewer performed review: 2022-03-16 11:24

Review time: 6 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

Overview of the manuscript A brief editorial of RASB, SGLT-2i and Finerenone for the treatment on DKD in the past 20 years was made. This editorial basically meets the requirements, however, some important issues still need to be revised. Details 1. The standard three-line table format should be used without any additional lines of columns in all tables. 2. The whole text is full of grammatical errors, presentation problems and typesetting problems, which seriously affect the reading and need to be polished by English professionals. 3. The author's title and thematic content settings seem to be a little thoughtless. First, as for "RASB to SGLT-2 inhibitors to Finerenone", RASB and SGLT-2i are both names of the drug type, while Finerenone is only a single drug, and Finerenone should be better changed to mineralocorticoid receptor antagonists (MRA). Other MRA drugs should also be mentioned meanwhile. Secondly, RASB to SGLT-2i to MRA does not seem to be a particularly reasonable expression, should be changed to RASB-SGLT-2i-MRA to express the history of this transition. Finally, the author's 20-year limit seems too arbitrary, for example, one of important studies for SGLT2-i, DECLARE, was not included. Therefore, the writing of the title and the time frame for the topic should be reconsidered. 4. The idea in Figure 1 is inspiring, but the clinical trials of DKD included seem incomplete. It would seem that the following major trials should be considered. List of clinical trials: 1) N Engl J Med. 1993;329(20):1456-1462. 2) J Hum Hypertens. 1996;10(3):185-192. 3) N Engl J Med. 1996;334(15):939-945. 4) Lancet. 2000;355(9200):253-259. 5) Lancet. 1997;349(9069):1857-1863. 6) Nephrol Dial Transplant. 2016;31(3):359-368. 7) N Engl J Med. 2004;351(19):1941-1951. 8) N Engl J Med. 2006;354(2):131-140. 9) Eur J Prev Cardiol. 2016;23(7):758-768. 10) N Engl J Med.



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

2019;380(24):2295-2306. 11) Nephrol Dial Transplant. 2020;35(2):274-282. 12) J Am Coll Cardiol. 2021;78(2):142-152. 5. In addition, the tests of different types of drugs should be classified in different colors in Figure 1, with one color for each type of drug and legends for readers to understand.



PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 76309

Title: Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05946247

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Ethiopia

Author's Country/Territory: India

Manuscript submission date: 2022-03-11

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-11 15:24

Reviewer performed review: 2022-03-20 22:51

Review time: 9 Days and 7 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

the finding of the manuscript is promising and clear, how ever, the methodology, hypothesis, and objective is not clear. why the author have no one to acknowledge? limitation of the study is not written, so how can a study with no clear data extraction method be published? or why the manuscript components including method and others, left un explained? if not applicable it should be indicated for reviewers



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 76309

Title: Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03650105

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: India

Manuscript submission date: 2022-03-11

Reviewer chosen by: Kai-Le Chang

Reviewer accepted review: 2022-04-21 06:34

Reviewer performed review: 2022-04-21 07:04

Review time: 1 Hour

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

We have carefully reviewed the manuscript, and the authors have answered most of our comments. As an editorial, the revision of this manuscript is satisfactory. Therefore, we agree to publish. Again, we remind the authors to finally check the article language expression and professional terms expression for the final publication. The authors have done an excellent job to the field and look forward to the publication.